PMID- 28320438
OWN - NLM
STAT- MEDLINE
DCOM- 20171013
LR  - 20191210
IS  - 1742-2094 (Electronic)
IS  - 1742-2094 (Linking)
VI  - 14
IP  - 1
DP  - 2017 Mar 20
TI  - Regulatory T cell frequency, but not plasma IL-33 levels, represents potential 
      immunological biomarker to predict clinical response to intravenous 
      immunoglobulin therapy.
PG  - 58
LID - 10.1186/s12974-017-0818-5 [doi]
LID - 58
AB  - BACKGROUND: Intravenous immunoglobulin (IVIG) is a polyspecific pooled 
      immunoglobulin G preparation and one of the commonly used therapeutics for 
      autoimmune diseases including those of neurological origin. A recent report in 
      murine model proposed that IVIG expands regulatory T (T(reg)) cells via induction 
      of interleukin 33 (IL-33). However, translational insight on these observations 
      is lacking. METHODS: Ten newly diagnosed Guillain-Barre syndrome (GBS) patients 
      were treated with IVIG at the rate of 0.4 g/kg for three to five consecutive 
      days. Clinical evaluation for muscular weakness was performed by Medical Research 
      Council (MRC) and modified Rankin scoring (MRS) system. Heparinized blood samples 
      were collected before and 1, 2, and 4-5 weeks post-IVIG therapy. Peripheral blood 
      mononuclear cells were stained for surface CD4 and intracellular Foxp3, IFN-gamma, 
      and tumor necrosis factor alpha (TNF-alpha) and were analyzed by flow cytometry. 
      IL-33 and prostaglandin E2 in the plasma were measured by ELISA. RESULTS: The 
      fold changes in plasma IL-33 at week 1 showed no correlation with the MRC and MRS 
      scores at weeks 1, 2, and >/=4 post-IVIG therapy. Clinical recovery following IVIG 
      therapy appears to be associated with T(reg) cell response. Contrary to murine 
      study, there was no association between the fold changes in IL-33 at week 1 and 
      T(reg) cell frequency at weeks 1, 2, and >/=4 post-IVIG therapy. T(reg) 
      cell-mediated clinical response to IVIG therapy in GBS patients was associated 
      with reciprocal regulation of effector T cells-expressing TNF-alpha. CONCLUSION: 
      T(reg) cell expansion by IVIG in patients with autoimmune diseases lack 
      correlation with IL-33. T(reg) cell frequency, but not plasma IL-33 levels, 
      represents potential immunological biomarker to predict clinical response to IVIG 
      therapy.
FAU - Maddur, Mohan S
AU  - Maddur MS
AD  - Institut National de la Sante et de la Recherche Medicale, Unite 1138, Paris, 
      75006, France.
AD  - Centre de Recherche des Cordeliers, Equipe- Immunopathologie et 
      immuno-intervention therapeutique, Paris, 75006, France.
AD  - Sorbonne Universites, UPMC Univ Paris 06, UMR S 1138, Paris, 75006, France.
AD  - Universite Paris Descartes, UMR S 1138, Paris, 75006, France.
AD  - Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, 
      Atlanta, GA, 30329, USA.
FAU - Stephen-Victor, Emmanuel
AU  - Stephen-Victor E
AD  - Institut National de la Sante et de la Recherche Medicale, Unite 1138, Paris, 
      75006, France.
AD  - Centre de Recherche des Cordeliers, Equipe- Immunopathologie et 
      immuno-intervention therapeutique, Paris, 75006, France.
AD  - Sorbonne Universites, UPMC Univ Paris 06, UMR S 1138, Paris, 75006, France.
FAU - Das, Mrinmoy
AU  - Das M
AD  - Institut National de la Sante et de la Recherche Medicale, Unite 1138, Paris, 
      75006, France.
AD  - Centre de Recherche des Cordeliers, Equipe- Immunopathologie et 
      immuno-intervention therapeutique, Paris, 75006, France.
AD  - Sorbonne Universites, UPMC Univ Paris 06, UMR S 1138, Paris, 75006, France.
FAU - Prakhar, Praveen
AU  - Prakhar P
AD  - Department of Microbiology and Cell Biology, Indian Institute of Science, 
      Bangalore, 560012, India.
FAU - Sharma, Varun K
AU  - Sharma VK
AD  - Institut National de la Sante et de la Recherche Medicale, Unite 1138, Paris, 
      75006, France.
AD  - Centre de Recherche des Cordeliers, Equipe- Immunopathologie et 
      immuno-intervention therapeutique, Paris, 75006, France.
AD  - Sorbonne Universites, UPMC Univ Paris 06, UMR S 1138, Paris, 75006, France.
AD  - Universite Paris Descartes, UMR S 1138, Paris, 75006, France.
FAU - Singh, Vikas
AU  - Singh V
AD  - Department of Microbiology and Cell Biology, Indian Institute of Science, 
      Bangalore, 560012, India.
FAU - Rabin, Magalie
AU  - Rabin M
AD  - Sorbonne Universites, UPMC Univ Paris 06, UMR S 1138, Paris, 75006, France.
FAU - Trinath, Jamma
AU  - Trinath J
AD  - Department of Microbiology and Cell Biology, Indian Institute of Science, 
      Bangalore, 560012, India.
FAU - Balaji, Kithiganahalli N
AU  - Balaji KN
AD  - Department of Microbiology and Cell Biology, Indian Institute of Science, 
      Bangalore, 560012, India.
FAU - Bolgert, Francis
AU  - Bolgert F
AD  - Reanimation Neurologique, Neurologie 1, Hopital de la Pitie-Salpetriere, Paris, 
      75651, France.
FAU - Vallat, Jean-Michel
AU  - Vallat JM
AD  - Centre de Reference 'Neuropathies Peripheriques Rares' et Service de Neurologie, 
      Hopital Universitaire Limoges, Limoges, 87042, France.
FAU - Magy, Laurent
AU  - Magy L
AD  - Centre de Reference 'Neuropathies Peripheriques Rares' et Service de Neurologie, 
      Hopital Universitaire Limoges, Limoges, 87042, France.
FAU - Kaveri, Srini V
AU  - Kaveri SV
AD  - Institut National de la Sante et de la Recherche Medicale, Unite 1138, Paris, 
      75006, France. srini.kaveri@crc.jussieu.fr.
AD  - Centre de Recherche des Cordeliers, Equipe- Immunopathologie et 
      immuno-intervention therapeutique, Paris, 75006, France. 
      srini.kaveri@crc.jussieu.fr.
AD  - Sorbonne Universites, UPMC Univ Paris 06, UMR S 1138, Paris, 75006, France. 
      srini.kaveri@crc.jussieu.fr.
AD  - Universite Paris Descartes, UMR S 1138, Paris, 75006, France. 
      srini.kaveri@crc.jussieu.fr.
FAU - Bayry, Jagadeesh
AU  - Bayry J
AD  - Institut National de la Sante et de la Recherche Medicale, Unite 1138, Paris, 
      75006, France. jagadeesh.bayry@crc.jussieu.fr.
AD  - Centre de Recherche des Cordeliers, Equipe- Immunopathologie et 
      immuno-intervention therapeutique, Paris, 75006, France. 
      jagadeesh.bayry@crc.jussieu.fr.
AD  - Sorbonne Universites, UPMC Univ Paris 06, UMR S 1138, Paris, 75006, France. 
      jagadeesh.bayry@crc.jussieu.fr.
AD  - Universite Paris Descartes, UMR S 1138, Paris, 75006, France. 
      jagadeesh.bayry@crc.jussieu.fr.
LA  - eng
PT  - Journal Article
DEP - 20170320
PL  - England
TA  - J Neuroinflammation
JT  - Journal of neuroinflammation
JID - 101222974
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
RN  - 0 (Interleukin-33)
RN  - K7Q1JQR04M (Dinoprostone)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Dinoprostone/metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Flow Cytometry
MH  - Follow-Up Studies
MH  - *Guillain-Barre Syndrome/blood/drug therapy/pathology
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunologic Factors/*therapeutic use
MH  - Interleukin-33/*blood
MH  - Male
MH  - Middle Aged
MH  - Outcome Assessment, Health Care
MH  - Predictive Value of Tests
MH  - Severity of Illness Index
MH  - Statistics, Nonparametric
MH  - T-Lymphocytes, Regulatory/*pathology
PMC - PMC5360043
OTO - NOTNLM
OT  - Clinical response
OT  - Guillain-Barre syndrome
OT  - IL-33
OT  - IVIG
OT  - Regulatory T cells
OT  - TNF-alpha
OT  - Treg cells
EDAT- 2017/03/23 06:00
MHDA- 2017/10/14 06:00
PMCR- 2017/03/20
CRDT- 2017/03/22 06:00
PHST- 2016/10/27 00:00 [received]
PHST- 2017/02/18 00:00 [accepted]
PHST- 2017/03/22 06:00 [entrez]
PHST- 2017/03/23 06:00 [pubmed]
PHST- 2017/10/14 06:00 [medline]
PHST- 2017/03/20 00:00 [pmc-release]
AID - 10.1186/s12974-017-0818-5 [pii]
AID - 818 [pii]
AID - 10.1186/s12974-017-0818-5 [doi]
PST - epublish
SO  - J Neuroinflammation. 2017 Mar 20;14(1):58. doi: 10.1186/s12974-017-0818-5.